Most Claims Survive In Royalty Spat Over HPV Drug

Law360, New York (May 26, 2009, 12:00 AM EDT) -- A Delaware judge has let the majority of claims stand in a breach of contract suit brought against MedImmune Inc. and Glaxo Group Ltd. over human papillomavirus vaccine Cervarix, but has dismissed claims of unjust enrichment and unfair competition, among others.

Judge Joseph R. Slights III of the Superior Court for the State of Delaware allowed most of the 10 counts brought by the Boyce Thompson Institute for Plant Research to continue — including the central claim of breach of contract.

However, “in the face of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.